ArticlePloS one2025
Antimalarial and neuroprotective effects of ethanolic extracts of the five-flower remedy in an experimental cerebral malaria model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral malaria (CM), a life-threatening consequence of Plasmodium falciparum infection, is associated with a high fatality rate and long-term brain impairment in survivors. Despite advances in malaria treatment, effective therapies to mitigate the severe neurological consequences of CM remain limited. Consequently, novel antimalarial drugs with different mechanisms or neuroprotective advantages are urgently required. This study aimed to explore the potential antimalarial and neuroprotective properties of the five-flower remedy (FFR), a traditional herbal formulation, in experimental cerebral malaria (ECM). Male C57BL/6 mice were induced with Plasmodium berghei ANKA to establish the ECM model. The ethanolic extract of FFR (600 mg/kg) was assessed both as a monotherapy and in combination with artesunate and administered for seven consecutive days starting at the onset of CM symptoms. Parasitemia levels, clinical progression, behavioral changes, and histopathological analysis of brain tissue were analyzed. The results revealed that the ethanolic extract of FFR alone improved outcomes in ECM, while its combination with artesunate significantly reduced parasitemia levels (80%), increased survival rates, reduced neurological deficits, and mitigated brain inflammation and behavioral changes. Histological analysis revealed decreased brain hemorrhage, leukocyte infiltration, and neuronal apoptosis. These promising results suggest that combining artesunate with FFR extract could be a valuable additional treatment for CM. This combination not only improves survival rates but also helps protect the brain by reducing inflammation, neurological damage, and behavioral changes. Further studies are needed to elucidate its drug interaction, mechanisms of action and potential clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.